NEW YORK (GenomeWeb) – WaferGen Bio-systems announced today that it expects to report a 62 percent rise in fourth quarter revenues while meeting its full-year revenue guidance.

For the three-month period ended Dec. 31, WaferGen's revenues are expected to be $3.9 million compared with $2.4 million in the same period the year before. The company said its revenues for 2016 are expected to be approximately $10.7 million, in line with previous guidance of $10 million to $12 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers test gene therapy targeting a different cancer protein in a new trial, the New York Times reports.

Pennsylvania State University researchers found that salivary microRNAs could predict which kids would have longer concussion symptoms, according to NPR.

The Associated Press reports Alex Azar, the new Department of Health and Human Services secretary nominee, made millions of dollars as a pharmaceutical executive.

In PNAS this week: immune profiling of breast cancer, transposable element patterns in rice, and more.

Dec
05
Sponsored by
Agilent

This webinar will discuss a molecular barcode-based error correction method that enables combined mutation detection and DNA copy number profiling through circulating tumor DNA sequencing.